A study in young children with cystic fibrosis (CF) shows that low chest radiograph scores are associated with more frequent pulmonary exacerbations, and the use of antibiotics is beneficial when respiratory symptoms increase. Although it’s been established that pulmonary exacerbations lead to a decline in lung function in older children and…
News
Using a cystic fibrosis patient’s tissue to grow mini-guts in a lab has become easier and is  available to more scientists who want to use it both to study the disease and test patients’ response to therapies. Stemcell Technologies, a Canadian biotechnology company, has released two new lines…
ProQR Therapeutics and Galapagos are working together on a new approach to treating the tissue scarring seen in cystic fibrosis. The collaboration will take advantage of ProQR’s proprietary next-generation RNA technology to develop axiomer editing oligonucleotides that can fight the fibrosis-promoting agents Galapagos has identified. “In this collaboration we…
Celtaxsys has obtained financing for a Phase 3 clinical trial of acebilustat as a treatment for cystic fibrosis. Acebilustat inhibits an enzyme that takes part in the production of a substance called leukotriene B4 (LTB4) that promotes an immune response known as inflammation. Scientists believe LTB4 plays a key role…
A possible inhalable treatment for antibiotic-resistant bacterial infections in people with cystic fibrosis due to Pseudomonas aeruginosa now has a U.S. patent and is being readied for a first clinical trial, Novoclem Therapeutics announced. The patent (No. 9,850,322) was issued to the University of North Carolina (UNC) at Chapel Hill where the…
The most influential cystic fibrosis advocacy groups in the United States and Europe have endorsed the idea of a Phase 1 clinical trial to test a triple-combo therapy that Proteostasis Therapeutics has developed, the company announced. Proteostatis said the endorsements came from the Cystic Fibrosis Foundation’s and European CF Society’s clinical…
Galapagos is advancing its development of a range of cystic fibrosis (CF) treatments intended for use in combinations — either with already approved CF therapies or with its own compounds — the Belgian biotech company announced. Phase 2 trials Among the advances is completion of a Phase 2 trial…
Researchers in Canada found new blood biomarkers that can more accurately detect cystic fibrosis (CF) in newborns than standard screening methods — a discovery that could lead to improvements in early identification of this disease. The study, “Metabolic Signatures of Cystic Fibrosis Identified in Dried Blood Spots for Newborn Screening Without…
Synspira received an award of up to $3 million from the Cystic Fibrosis Foundation to advance the clinical development of its lead candidate, SNSP113, for the treatment of pulmonary complications in cystic fibrosis (CF). Synspira is a company developing a…
A number of cystic fibrosis discoveries, therapy advances and other developments were reported by Cystic Fibrosis News Today during 2017. Now that the year is over, it’s time to review the articles that appealed most to our readers. Here are the 10 most-read articles of 2017, with a brief description of what…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.